Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.67 Consensus PT from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been assigned an average rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $34.00.

A number of research analysts recently weighed in on CPRX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 7th. Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Citigroup raised their price target on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th.

Catalyst Pharmaceuticals Stock Down 0.3%

NASDAQ:CPRX opened at $24.24 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of 14.34, a price-to-earnings-growth ratio of 0.72 and a beta of 0.75. Catalyst Pharmaceuticals has a twelve month low of $19.05 and a twelve month high of $26.58. The business has a 50 day moving average price of $23.85 and a two-hundred day moving average price of $22.34.

Insider Buying and Selling

In other news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares of the company’s stock, valued at $54,870. This trade represents a 91.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its position in shares of Catalyst Pharmaceuticals by 39.1% in the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after purchasing an additional 60,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Catalyst Pharmaceuticals by 5.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after purchasing an additional 3,800 shares during the period. Goldman Sachs Group Inc. grew its holdings in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after buying an additional 262,392 shares during the period. Finally, Intech Investment Management LLC increased its position in Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 4,261 shares during the period. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).